» Articles » PMID: 25108195

Estrogen Receptor-alpha 36 Mediates the Anti-apoptotic Effect of Estradiol in Triple Negative Breast Cancer Cells Via a Membrane-associated Mechanism

Overview
Specialties Biochemistry
Biophysics
Date 2014 Aug 10
PMID 25108195
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

17β-Estradiol can promote the growth and development of several estrogen receptor (ER)-negative breast cancers. The effects are rapid and non-genomic, suggesting that a membrane-associated ER is involved. ERα36 has been shown to mediate rapid, non-genomic, membrane-associated effects of 17β-estradiol in several cancer cell lines, including triple negative HCC38 breast cancer cells. Moreover, the effect is anti-apoptotic. The aim of this study was to determine if ERα36 mediates this anti-apoptotic effect, and to elucidate the mechanism involved. Taxol was used to induce apoptosis in HCC38 cells, and the effect of 17β-estradiol pre-treatment was determined. Antibodies to ERα36, signal pathway inhibitors, ERα36 deletion mutants, and ERα36-silencing were used prior to these treatments to determine the role of ERα36 in these effects and to determine which signaling molecules were involved. We found that the anti-apoptotic effect of 17β-estradiol in HCC38 breast cancer cells is in fact mediated by membrane-associated ERα36. We also showed that this signaling occurs through a pathway that requires PLD, LPA, and PI3K; Gαs and calcium signaling may also be involved. In addition, dynamic palmitoylation is required for the membrane-associated effect of 17β-estradiol. Exon 9 of ERα36, a unique exon to ERα36 not found in other identified splice variants of ERα with previously unknown function, is necessary for these effects. This study provides a working model for a mechanism by which estradiol promotes anti-apoptosis through membrane-associated ERα36, suggesting that ERα36 may be a potential membrane target for drug design against breast cancer, particularly triple negative breast cancer.

Citing Articles

Antiproliferative Role of Natural and Semi-Synthetic Tocopherols on Colorectal Cancer Cells Overexpressing the Estrogen Receptor β.

Falsetti I, Palmini G, Zonefrati R, Vasa K, Donati S, Aurilia C Int J Mol Sci. 2025; 26(5).

PMID: 40076925 PMC: 11900421. DOI: 10.3390/ijms26052305.


Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.

Cohen D, Dennis C, Deng J, Boyan B, Schwartz Z JBMR Plus. 2024; 8(5):ziae041.

PMID: 38644978 PMC: 11032217. DOI: 10.1093/jbmrpl/ziae041.


ER-α36 is involved in calycosin inhibition of IL-6 production in macrophages.

Wu G, Qi G, Liu Y, Gan J, Xie C, Wu Q J Cell Mol Med. 2023; 28(1):e18037.

PMID: 37974543 PMC: 10805506. DOI: 10.1111/jcmm.18037.


14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.

Garan L, Xiao Y, Lin W Proc Natl Acad Sci U S A. 2022; 119(43):e2209211119.

PMID: 36252018 PMC: 9618134. DOI: 10.1073/pnas.2209211119.


Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Shanta K, Nakayama K, Hossain M, Razia S, Ishibashi T, Ishikawa M Curr Oncol. 2022; 29(6):4020-4033.

PMID: 35735430 PMC: 9221871. DOI: 10.3390/curroncol29060321.


References
1.
Li L, Haynes M, Bender J . Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A. 2003; 100(8):4807-12. PMC: 153637. DOI: 10.1073/pnas.0831079100. View

2.
Jatoi I, Chen B, Anderson W, Rosenberg P . Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 2007; 25(13):1683-90. DOI: 10.1200/JCO.2006.09.2106. View

3.
Hartmann J, Fels L, Knop S, Stolt H, Kanz L, Bokemeyer C . A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000; 18(3):281-9. DOI: 10.1023/a:1006490226104. View

4.
DiMartino L, Demontis B, Mitchell I, Hayward S, Deshpande N . A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mastectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report. Anticancer Res. 1991; 11(2):869-72. View

5.
Herranz N, Pasini D, Diaz V, Franci C, Gutierrez A, Dave N . Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008; 28(15):4772-81. PMC: 2493371. DOI: 10.1128/MCB.00323-08. View